Antibodies News and Research

RSS

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

Researchers in the United States have demonstrated the effectiveness of the Pfizer-BioNTech, Moderna, and Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccines at reducing the need for emergency care or hospitalization following breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Researchers prepare for next coronavirus pandemic

Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004.

17 Jun 2021

New study may lead to more effective and powerful COVID-19 vaccines

A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open the door to even more effective and powerful vaccines against the coronavirus and its rapidly emerging variants keeping the global pandemic smoldering.

17 Jun 2021

Corticosteroids may effectively treat children who develop a serious disorder after COVID-19

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after COVID-19 infection.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

The researchers found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations. The results of this study are posted to the medRxiv* preprint server.

16 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

New antibody testing study finds evidence of early COVID-19 infections in the U.S.

A new antibody testing study examining samples originally collected through the National Institutes of Health's All of Us Research Program found evidence of SARS-CoV-2 infections in five states earlier than had initially been reported.

15 Jun 2021

Study may offer an unexpected pathway for targeted treatment of brain tumors

In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

15 Jun 2021

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

A new bioRxiv* preprint demonstrates how a combination of antibodies to two different regions on the viral spike could enhance neutralization efficiency as well as prevent the emergence of resistant variants.

15 Jun 2021

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

A new study, released as a preprint on the bioRxiv* server, describes the biological effects induced by mutations in two circulating VOCs. These are the alpha and beta strains, also called B.1.1.7 and B.1.351, respectively.

15 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

The Role of Nanoparticles for Drug Delivery

In this interview, Mark Bumiller, Technology Manager at Entegris talks to News Medical Life Sciences about the role nanoparticles can play in drug delivery.

From Entegris, Inc. 15 Jun 2021

Analysis of COVID-19 patients with repeatedly positive SARS-CoV-2 tests

New research published on the medRxiv preprint server provides a detailed analysis of COVID-19 patients who had repeated positive PCR tests for SARS-CoV-2 infection in a large US COVID-19 electronic health record (EHR) database.

15 Jun 2021

REGEN-COV antibody cocktail shown to significantly lower SARS-CoV-2 viral load

In human trials, the interim analysis of 275 participants showed REGEN-COV quickly reduced viral loads. Moreover, this reduction was much faster in people who did not have a high viral load when they started treatment.

15 Jun 2021

Researchers examine the importance of time after COVID-19 vaccination

A new study has been published on the medRxiv* preprint server, which deals with the importance of time post-vaccination based on the quantification of VOC immune evasion. The current study developed a toy model to estimate the effectiveness of the vaccines against VOC over time. Researchers have shown that the estimated value is highly dependent on time post-vaccination. Additionally, this model can describe the implications of changes in vaccine efficacy against VOC.

14 Jun 2021

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.

14 Jun 2021

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

A new study, released as a preprint on the bioRxiv* server, presents a new monoclonal antibody (MAb) called DZIF-10c that powerfully neutralizes SARS-CoV-2, including the current variants of concern (VOCs). With high bioavailability in the lungs and wide distribution in the body, the antibody was able to prevent SARS-CoV-2 infection in mice after intranasal administration.

14 Jun 2021

Antibodies News and Research

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Full vaccination prevents emergency care and hospitalization in cases of breakthrough COVID-19

Researchers prepare for next coronavirus pandemic

New study may lead to more effective and powerful COVID-19 vaccines

Corticosteroids may effectively treat children who develop a serious disorder after COVID-19

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Prior vaccination against diphtheria and tetanus associated with less severe COVID-19

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

New antibody testing study finds evidence of early COVID-19 infections in the U.S.

Study may offer an unexpected pathway for targeted treatment of brain tumors

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

The Role of Nanoparticles for Drug Delivery

Analysis of COVID-19 patients with repeatedly positive SARS-CoV-2 tests

REGEN-COV antibody cocktail shown to significantly lower SARS-CoV-2 viral load

Researchers examine the importance of time after COVID-19 vaccination

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo